- ¥123bn
- ¥159bn
- ¥30bn
Factbox: Roche enters obesity drugs race with $2.7 bln Carmot deal
Factbox: Roche enters obesity drugs race with $2.7 bln Carmot deal
Factbox: Pfizer's weight loss ambitions hit roadblock
9-MTH group results (IFRS)
Brief: Sosei Group Corp - Sosei Heptares' Partner, Pfizer, Progresses Its Glp-1 Receptor Agonist Pf-06954522 Into A Phase 1 Trial
Brief: Sosei Group Corp -Sosei Heptares' Partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects Of Nbi-1117570 In Healthy Adults
6-MTH group results (IFRS)
Sosei buys Idorsia Pharmaceuticals' Japan, Korea units for $466 mln (updated)
Sosei buys Idorsia Pharmaceuticals' Japan, Korea units for $466 million - Nikkei
Brief: Sosei Group Has Bought Swiss Idorsia Pharmaceuticals' Japan And South Korea Businesses For About 65 Billion Yen - Nikkei
Brief: Sosei Heptares Says Will Explore Next Steps With Pfizer For Future Development Of Lotiglipron
Factbox: Drugmakers bulk up with bets on weight-loss treatments
Q1 group results (IFRS)
Brief: Sosei Group Corp - Announces Change Of Market Listing Segment To Tokyo Stock Exchange Prime Market
2022 group results (IFRS)
Brief: Sosei Heptares Says Partner Tempero Bio Received FDA Clearance To Advance Clinical Development Of TMP-301
Brief: Sosei Heptares' Partner Pfizer Progresses Its Oral Glp-1 Receptor Agonist Pf-07081532 Into Phase 2 Clinical Trials
Brief: Sosei Heptares Says Entered Multi-Target Collaboration And License Agreement In Diabetes And Metabolic Diseases With Eli Lilly
Brief: Sosei Heptares Receives $10 Mln Milestone Payment In Discovery Collaboration With Abbvie Targeting Inflammatory Diseases